Imaging Boom Drives Cancer Detection and Healthcare Growth
Major growth factor consist of large number of clinics have adopted tools for cancer detection like MRI, CT-scans and other. This has led to growth in healthcare sector and global economy. It is also a milestone for healthcare services.
Key Growth Drivers and Opportunities
Growing Incidence of Cancer: The increasing prevalence and incidences of various types of cancer like lung cancer and breast cancer, help the cancer diagnostics market to grow significantly during the forecast period. According to estimates, 1 in 100 (or 1% yearly) of those 70 years of age or over lost their lives to cancer in 2019. Overall death toll is rising in tandem with the world's population growth. From roughly 46 million in 1990 to 56 million in 2019, there have been more fatalities. Most cancer deaths occur in elderly adults.
Rising Expenditure of Healthcare: The cost estimates cover both prescription medications taken by mouth and medical treatments for cancer. The most expensive medical services nationally were linked to non-Hodgkin lymphomas, as well as cancers of the prostate, lung, colon, and female breast. Medical services care costs, which comprise Medicare payments as well as patient obligations for all billed medical services, such as hospitalizations, outpatient hospital services, physician/supplier services, infusion or injectable drug, durable medical equipment, and hospice care, were estimated from Medicare Parts A and B claims.
Challenges
The implementing cancer diagnostics can require significant upfront investment, including the cost of the software itself, customization, and integration with existing systems. This can be a barrier for smaller hospitals with limited budgets. The regulatory landscape for cancer diagnostics is constantly evolving, with new guidelines and requirements emerging regularly. Keeping up with these changes and adjusting reporting practices accordingly can be a daunting task for companies
Innovation and Expansion
Guardant, Boehringer Team Up on HER2 NSCLC Liquid Biopsy
In December 2024, the Guardant Health, Inc. announced a partnership with Boehringer Ingelheim aimed at obtaining regulatory approval and advancing the commercialization of the Guardant360 CDx liquid biopsy.
This partnership is all about using liquid biopsy as a companion diagnostic (CDx) for zongertinib. Zongertinib is a new type of drug called a covalent tyrosine kinase inhibitor (TKI) designed to specifically target HER2 in non-small cell lung cancer (NSCLC), while minimizing the impct on the epidermal growth factor receptor (EGFR).
GE, GenesisCare Partner to Tackle Cancer and Heart Disease
In November 2020, GE Healthcare entered into partnership with GenesisCare to improve patient outcomes for the two biggest health burdens globally, cancer and heart disease. GE Healthcare will provide CT, MRI, PET/CT, SPECT, digital mammography, and ultrasound equipment to GenesisCare's 440+ cancer and cardiovascular disease treatment centers across Australia, the US, the UK, and Spain
This partnership is all about boosting how accurately we can diagnose conditions and making treatment plans smoother, all thanks to state-of-the-art imaging tech. With GE Healthcare's innovative tools, GenesisCare can really speed up spotting issues early on and providing tailored care for folks dealing with cancer or heart-related conditions.
Inventive Sparks, Expanding Markets
The Key players in the global cancer diagnostics market includes, Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company among others. As major key players, they're effectively striving in innovation to make sure consumers globally can benefit from modern healthcare tech and to really elevate the overall experience for patients everywhere.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
36 minutes ago
- Medscape
Dire Warnings, Rosy Future: Medicare at 60
The creation of Medicare in 1965 was hailed as a watershed for the social safety net, offering millions of older Americans financial security and freedom from worry about their medical expenses. But critics of the legislation cast dire warnings about what the law would do to the nation's physicians, the doctor-patient relationship, and even the country's way of life. Who was right? To mark the 60th anniversary of Medicare, Medscape asked leaders in healthcare, American history, and public policy to reflect on the words of the program's earliest champions and critics. Comments have been edited for length and clarity. Democratic presidential nominee John F. Kennedy, August 14, 1960. Then-Senator John F. Kennedy , spoke in support of a national insurance program for the elderly at an event on August 14, 1960: "Three out of every five of these [people over age 65] — more than 9.5 million people — must struggle to survive on an income of under $1000 a year. …This poverty and hardship turn into heartbreak and despair when illness threatens. Medicines and drugs are more expensive than ever before — hospital rates have more than doubled — doctor bills have skyrocketed. …Those over 65 suffer from chronic diseases at almost twice the rate of our younger population — they spend more than twice as many days restricted to bed — and they must visit a doctor twice as often." Commentary Keith Wailoo, PhD, Henry Putnam University professor of history and public affairs at Princeton University and past president of the American Association for the History of Medicine: "An important backdrop behind JFK's comment is reflecting 10 years prior on the failure of President Harry Truman's national health insurance proposals. The frustrations and the stories he's telling were evident after World War II. Keith Wailoo, PhD "He's describing a landscape where — in the course of the war — private insurance became more attached to employment, wage freezes meant that companies couldn't raise wages, unions lobbied and employers argued that benefits could be increased, and as a result of a momentous Supreme Court ruling, health insurance became increasingly a byproduct of employment. Healthcare costs were rising, and insurance was becoming a passage point to getting hospital care. "The face of the poor and medical needy were the elderly by 1960. They were not working, and because of advancing life expectancy, there was more infirmity and yet they were locked out of the system. "So we've recreated the world, and with that we have also changed people's expectations about what they can hope for." Ronald Reagan and the American Medical Association, 1961 audio recording on LP. In 1961, Ronald Reagan released a speech against a proposed bill that would cover hospital costs for the elderly. The effort was later revealed to be part of a campaign by the American Medical Association (AMA) to quash efforts to create a national health insurance program. Reagan said: "[The bill] was simply an excuse to bring about what they wanted all the time, socialized medicine. … First, you decide that the doctor can have so many patients, they're equally divided among the various doctors by the government. But then the doctors aren't equally divided geographically. So a doctor decides he wants to practice in one town, and the government has to say to him, 'You can't live in that town. They already have enough doctors,' and from here, it's only a short step to dictating where he will go." Commentary Reid B. Blackwelder, MD, associate dean for graduate medical and continuing education, DIO, Quillen College of Medicine, East Tennessee State University, and past president of the American Academy of Family Physicians: "Reagan's warning that nationalized health insurance would lead to government direction for where physicians practice has not happened. Physicians have the freedom to accept insurance or not and to practice anywhere they want. Sadly, our country is facing increasing healthcare deserts for various reasons. Reid B. Blackwelder, MD "We already had a serious and growing access problem for patients. Now, patients in rural areas especially are losing even more access to primary care physicians and specialists as rural hospitals shut down and physicians like obstetricians stop practicing outside of urban areas. "Ironically, Medicare is perhaps the most lenient health insurance in terms of providing that freedom of choice Reagan described for patients. Because Medicare is popular and widely accepted by patients and physicians, patients can readily choose the physician they want, including subspecialists. On the other hand, for-profit insurance has created significant limits on which physicians a patient may select based on acceptance of that insurance and cost. It can be difficult for a patient to see the physician of their choice." Dr Edward Annis ( left ), holding an anatomical model of a human heart, speaks with TV host Johnny Carson ( right ) on the The Tonight Show , December 11, 1963. Edward Annis, MD , chairman of the AMA 's speakers' bureau — and later president of the association — appeared in a televised May 21, 1962, address about the proposed King-Anderson bill, an early iteration of what would become the legislation that created Medicare. Annis said: 'It wastefully covers millions who do not need it, it heartlessly ignores millions who do need coverage. It is not true insurance. It will create an enormous and unpredictable burden on every working taxpayer. It offers sharply limited benefits. And it will serve as a forerunner of a different system of medicine for all Americans.' Commentary Jonathan Oberlander, PhD, professor of social medicine at the University of North Carolina at Chapel Hill, and editor of the Journal of Health Politics, Policy and Law: "The AMA's overheated rhetoric against Medicare did not age well. Doctors would later face challenges to their clinical autonomy, as Annis had feared, but that intrusion came from private managed care insurers trying to control skyrocketing costs, not Medicare. "Yet the AMA was right about one thing. Although they didn't admit it during the 1960s, Medicare's architects saw the program as the first step to universal health insurance, and after covering the elderly, they hoped to next turn to children and eventually cover everyone via government insurance. Medicare for All was the aspiration. "That did not happen, and although Medicare expanded eligibility in 1972 to cover persons with permanent disabilities and end-stage renal disease — six decades after the program's enactment — its primary beneficiaries are still older Americans, an outcome that would have stunned its creators. "After Medicare's enactment in 1965, the AMA's opposition to the program faded, much to Annis' consternation. Forty years later, he still expressed regret that the association did not take a more 'militant' stand highlighting the program's problems." Dr Edward Annis (right) with Dr Arthur Fleming. Annis continued: "This King-Anderson Bill is a cruel hoax and illusion. … It will come between the patient and his doctor." Commentary Reid B. Blackwelder, MD, associate dean for graduate medical and continuing education, DIO, Quillen College of Medicine, East Tennessee State University, and past president of the American Academy of Family Physicians "The special and powerful relationship between patients and physicians is a real thing. Medicare did not damage it. Other insurance coverage did not damage it. Having any insurance coverage is one of the foundations of getting to good health outcomes. The other is having a source of comprehensive care. Patients need both. "The very real threat to the physician-patient relationship that is accelerating today is from legislative intrusions into the patient room. When laws are passed that make even just exploring options with patients around things like reproductive health a criminal offense, government has overstepped. "When laws are enacted that require a physician to call their lawyer rather than a specialty consult before providing life-saving care, we have entered a new and dangerous era of governmental oversight. Recent laws have done more damage to the sanctity of the physician-patient relationship that Medicare actually helped improve." Rep. Durward Gorham Hall, 1969 Representative Durward Gorham Hall, MD (R, Missouri), made these remarks below during debates on Medicare in the House of Representatives: "This conflict is testing whether art and science of medicine will be permitted to grow and flourish in freedom and competitively, or whether progress in medicine will be stunted and shriveled by an excess of Government control." Commentary Jonathan B. Jaffery, MD, MS, MMM, chief healthcare officer at the Association of American Medical Colleges: "By supporting the training of physicians, Medicare helps create the physician workforce for future generations of Americans, crucial for the care of an aging population. And through iterative developments over the last 60 years, such as Coverage with Evidence Development or the Center for Medicare and Medicaid Innovations, the Medicare program — coupled with federal investments in biomedical research — has been able to support innovations in both medical technologies and models of care delivery that continue to improve the lives and well-beings of millions. Jonathan B. Jaffery, MD "The reality is, prior to 1965, many elderly Americans with healthcare needs were forced to rely on financial support from their families or spend all their life's savings, hope for charity care, or forego care altogether. And of course, the cost of care has only skyrocketed, so that in 2025 even very high-net worth individuals would struggle to cover the costs of a lengthy hospitalization or extended illness, let alone the price tag of many new life-saving medications." Hall continued: "The result will inescapably be third-party intrusion in the practice of hospitalization and medicine. His diagnostic and therapeutic decisions would be subject to disapproval by those controlling the expenditure of tax money." Commentary G. William Hoagland, senior vice president, Bipartisan Policy Center, former executive at Cigna, and former US Senate staffer "Representative Hall was prescient in his observation about the future of healthcare resulting from the creation of Medicare. The 60-year history of the Medicare program, particularly since the enactment of the Tax Equity and Fiscal Responsibility Act in 1982, the Medicare Modernization Act in 2003, and the Patient Protection and Affordable Care Act in 2010, has resulted in the 'corporatization' of healthcare. G. William Hoagland "Today, Medicare Advantage, dominated by 'third-party' corporate insurance companies, has transferred the physician's independent decisions to actuaries and corporate financial decision makers. The result has also been horizontal consolidation of what were locally controlled entities to nationally or regionally controlled corporations along with vertical consolidation of payers and care delivery entities. "The impact of these changes, along with dramatic scientific advances in diagnosis with advanced treatment protocols, precipitating higher healthcare utilization, has not been to reduce costs but to in fact increase healthcare costs." President Lyndon Johnson ( left ) flips through the pages of the Medicare bill so former President Harry Truman ( right) can see it. Following passage of the Social Security Amendments of 1965 out of the Senate by a vote of 68-21, President Lyndon B. Johnson said: "It will help pay for care in hospitals. If hospitalization is unnecessary, it will help pay for care in nursing homes or in the home. And wherever illness is treated — in home or hospital — it will also help meet the fees of doctors and the costs of drugs." Commentary Bruce Leff, MD, professor of medicine and director of the Center for Transformative Geriatric Research, Johns Hopkins University School of Medicine in Baltimore: "Johnson's statement regarding care at home was appropriate for the mid-1960s. To this day, skilled home healthcare remains the most used home-based service by Medicare beneficiaries. "Since Medicare was enacted, a bevy of evidence-based home care delivery models have been developed and proven. These home-based models span the care continuum including home and community-based services, home-based primary care, transitional care, and home-based palliative care. Bruce Leff, MD "Unfortunately, Medicare payment policies incentivized the centralization of care in facilities and a facility-centric culture of care delivery. Care delivery hasn't kept pace with the needs of an aging population with a high prevalence of homebound older Americans or with the advances that enable even hospital care to be delivered to patients in their preferred setting, their homes. "The hospital of the future will comprise of emergency departments, operating rooms, and intensive care units. Most other care can and will be provided in the home setting. We have all the pieces to develop this future home-based care vision. Achieving this vision will require a culture shift with associated payment and regulatory enhancements, ongoing attention to improvements in technology, logistics, and data management." An elderly woman shows her gratitude to President Lyndon B. Johnson for his signing of the Medicare healthcare bill in April 1965. Johnson continued: "Older citizens will no longer have to fear that illness will wipe out their savings, eat up their income, and destroy lifelong hope of dignity and independence. For every family with older members, it will mean relief from the often-crushing responsibilities of care." Commentary Gretchen Jacobson, PhD, vice president, Medicare program, Commonwealth Fund: Gretchen Jacobson, PhD "One third of Medicare beneficiaries said in 2023 that it was difficult to afford healthcare costs. More than 1 in 5 beneficiaries reported in 2023 delaying or skipping needed healthcare because of the cost. Similarly, some Medicare beneficiaries trade off paying for other necessities to pay for needed healthcare. The lack of a limit on out-of-pocket spending on hospital and physician services for traditional Medicare has, for most traditional Medicare enrollees, necessitated purchasing supplemental insurance coverage. Yet, the limited availability of this supplemental coverage has resulted in more beneficiaries enrolling in Medicare Advantage and high underinsurance rates among those in traditional Medicare without supplemental coverage. "Medicare beneficiaries who do not have a family caregiver and cannot afford to pay out-of-pocket for a formal caregiver are typically forced to deplete their financial resources to qualify for Medicaid coverage, the largest payer for long-term care in the US."
New York Post
an hour ago
- New York Post
Mom paralyzed after Botox-like injections ‘poisoned' her body: ‘Worst decision I've ever made'
A mom who was left with partial paralysis thought she was 'slowly dying' after Botox-like injections 'poisoned' her body – and says she 'learned the cost of beauty the hard way.' Amanda Wolaver, 33, had been getting routine anti-wrinkle injections for 10 years with 'no issues' until a top-up left her with 'severe' headaches. She went to the hospital the next day after waking up 'unable to move,' but a CT scan revealed 'nothing was wrong.' 9 Amanda Wolaver (right), 33, had been getting routine anti-wrinkle injections for 10 years with 'no issues' until a touch-up left her with 'severe' headaches. Amanda Wolaver / SWNS Over 16 months, her symptoms worsened – she became housebound for four months and everyday tasks like showering and doing her make-up became a struggle – and an MRI revealed that she even suffered from TIA strokes. After $30,000 in tests later, a neurologist finally diagnosed Amanda with iatrogenic botulism. The rare neuromuscular disease is caused by botulinum neurotoxins – the active ingredient in Botox. Although there is no specific treatment, Amanda is 'recovering slowly' and letting time detoxify her body. Amanda, a sales director from Goodhope, Georgia, said: 'It's almost been two years and I still don't feel normal. 9 Wolaver went to the hospital the next day after waking up 'unable to move,' but a CT scan revealed 'nothing was wrong.' Amanda Wolaver / SWNS 'Never did I think this might happen to me. 'It was the worst decision I've ever made. 'I couldn't be the mother I wanted for my three children, Landen, 16, Braxton, 11, and Havyn, 5. 'As I was essentially a vegetable, unable to move, walk, drive, or do anything I love. 'But I'm grateful for the support of my husband, Josh, 39, who was there for me. 9 Over 16 months, her symptoms worsened – she became housebound for four months and everyday tasks like showering and doing her make-up became a struggle. Amanda Wolaver / SWNS 'I want my experience to educate others about botulinum toxins. 'I learned the cost of beauty the hard way.' Amanda paid $700 to have 104 units of Dysport – a Botox alternative she had never used before – injected into her forehead, crow's feet, and eleven lines in August 2023. 'I began developing this horrible migraine and thought if I slept it off, it would go away,' she said. 'However, when I woke up the next day, I couldn't function or string sentences together.' 9 An MRI revealed that Wolaver even suffered from TIA strokes. Amanda Wolaver / SWNS Botox and Dysport are neurotoxins that block muscle contractions to rid wrinkles, and both derive from botulinum toxin. Amanda visited the hospital and was told it was 'nothing to do with the injections.' 'They told me that it was probably just a severe migraine,' she said. 'But soon, my body felt like the floor was being ripped out from underneath me and that I'd collapse. 'My dizziness became so severe that I had to take Xanax to knock me out to sleep. 'I thought I was slowly dying.' 9 After numerous of testing, a neurologist finally diagnosed Amanda with iatrogenic botulism. Amanda Wolaver / SWNS Amanda visited doctors multiple times to find a cause and underwent a heart monitor implant and spinal tap surgeries. 'They thought I had MS at one point and an autoimmune disorder,' she added. 'I underwent around 10 to 15 different MRIs, CTs and multiple procedures. 'I felt like a lab rat.' Four months after her injections, a head and neck MR also revealed that the mom suffered from multiple TIA strokes. 9 Amanda, a sales director, said, 'It's almost been two years and I still don't feel normal.' Amanda Wolaver / SWNS 'That knocked me back,' she said. 'To be told I had suffered from multiple small strokes in my brain made me think that this would eventually kill me.' Her joint pain left her struggling to formulate sentences. 'My life was essentially ruined,' Amanda said. 9 'To be told I had suffered from multiple small strokes in my brain made me think that this would eventually kill me,' she continued. Amanda Wolaver / SWNS 'I lost friends and couldn't hang out with my family, as loud noises and strong smells would trigger my dizziness. 'So I couldn't even cook my kids' dinner or clean the house.' But it wasn't until she discovered a forum of people who had suffered Botox poisoning that it 'all came together.' In March 2025, she was diagnosed with iatrogenic botulism after doctors pinned the timing and correlation of her symptoms to her Dysport injections. 9 'I've cut out caffeine, soda, and even had my breast implants taken out in April to allow my body to detoxify itself,' she continued. Amanda Wolaver / SWNS 'It was a bittersweet moment,' she said. 'But there is no cure and no promise that I will be 100 per cent back to normal.' Six months later, Amanda still suffers daily with lasting effects. She said: 'I still get the occasional dizziness and I have changed my diet completely to make sure nothing bad is going in me. 9 'But now I want to create more awareness about the dangers of botulinum neurotoxins,' Wolaver said. Amanda Wolaver / SWNS 'I've cut out caffeine, soda, and even had my breast implants taken out in April to allow my body to detoxify itself. 'I don't care about my wrinkles at all now, and I'm getting more active and able to do more things with my family. 'But now I want to create more awareness about the dangers of botulinum neurotoxins. 'Hopefully, I can help prevent this from happening to others.'
Yahoo
3 hours ago
- Yahoo
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from 6-9 September 2025. The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company's antigen presenting cell (APC) activator, eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC). The global trial will enrol approximately 750 patients regardless of PD-L1 expression (Tumour Proportion Score or TPS of 0-100%) and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries. Immutep CMO, Stephan Winckels M.D., Ph.D, said, 'Our engagement to date with physicians in the lung cancer community, including at ELCC in Paris and ASCO in Chicago, has yielded encouraging feedback with a shared view of efti as a safe, easy-to-administer immunotherapy with strong efficacy across two 1L NSCLC trials. We look forward to continuing our investigator discussions at WCLC and ESMO around the pivotal TACTI-004 Phase III, which has the potential to change the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer, irrespective of their PD-L1 expression.' Details for the poster presentation:Title: TACTI-004, a Phase 3 trial of Eftilagimod Alfa plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1st line NSCLC Presenter: Dr. Martin Sebastian, University Hospital of Frankfurt, GermanySession: Clinical Trials in ProgressDate and Time: Tuesday, 9 September 2025 at 10:00 AM CEST The poster will be available on the Posters & Publications section of Immutep's website following the presentation. About Eftilagimod Alfa (efti)Efti is Immutep's proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a first-in-class antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system's ability to fight is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; in to access your portfolio
